Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION A live Pharma & Life Sciences Clinical and Evidence Strategy file in a 505(b)(2) program relying on literature plus a bridging study now turns on 505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate. Pediatric-plan strategist should state what that extract proves for whether the 505(b)(2) bridge is legally and scientifically enough.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; 505(b)(2) literature-to-product bridge table already has the discriminator after a payer demanding RWE the protocol cannot generate. 2. Keep Pause the pathway in force until 505(b)(2) literature-to-product bridge table is completed after a payer demanding RWE the protocol cannot generate for pediatric-plan strategist. 3. Treat 505(b)(2) literature-to-product bridge table as Escalate safety review because both readings appear after a payer demanding RWE the protocol cannot generate. 4. Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the decision the 505(b)(2) bridge is turns on in 505(b)(2) literature-to-product bridge table.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is. 2. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim pediatric-plan strategist would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a payer demanding RWE the protocol cannot generate and write the one fact that would move the 505(b)(2) bridge is for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate). The follow-on Clinical and Evidence Strategy action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the 505(b)(2) bridge is, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for pediatric-plan strategist - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - What changes the 505(b)(2) bridge is if a payer demanding RWE the protocol cannot generate is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others